ar1001
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Sep 1, 2018 (NCT03625622)
Timeline
Indications
Studied for
Mechanism of action
Phosphodiesterase 2 and 5 (PDE2 and PDE5) inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05531526 | Phase 3 | Dec 31, 2022 | AriBio Co., Ltd. |
| NCT03625622 | Phase 2 | Sep 1, 2018 | AriBio Co., Ltd. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AriBio Co., Ltd. | For profit | 2 | 2 | 2 | 2018 |
1 organizations
Page 1 / 1